A method for stabilizing and isolating multiple biological targets comprised in a cell-containing bodily fluid, said method comprising (A) contacting a cell-containing bodily fluid with a stabilizing composition comprising one or more of the following stabilizing agents: (a) at least one primary, secondary or tertiary amide, (b) at least one poly(oxyethylene) polymer, and/or (c) at least one apoptosis inhibitor, thereby providing a stabilized cell-containing bodily fluid sample; (B) keeping the stabilized cell-containing bodily fluid sample for a stabilization period; and (C) processing the stabilized cell-containing bodily fluid sample in order to enrich three or more biological targets selected from the group consisting of —a cell subpopulation, —extracellular nucleic acids, —extracellular vesicles and —intracellular nucleic acids from the stabilized cell-containing bodily fluid. The method is advantageous and enables the multimodal analyses of different biological targets from a single stabilized cell-containing body fluid sample.

The present disclosure relates to methods of determining if a proliferative disorder such as cancer is resistant to treatment with a pyrrolobenzodiazepine (PBD) agent, such as a therapeutic antibody-drug conjugate (ADC) comprising a PBD warhead conjugated to an antibody (PBD-ADC). The present disclosure also describes methods of selecting subjects suitable for treatment with a PBD agent, and methods of reducing the resistance of a proliferative disorder to a PBD agent.

The present invention provides a kit or device for the detection of biliary tract cancer, and a method for detecting biliary tract cancer. The present invention relates to a kit or device for the detection of biliary tract cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting biliary tract cancer, comprising measuring the miRNA in vitro.

It is intended to provide a kit or a device for the detection of breast cancer and a method for detecting breast cancer. The present invention provides a kit or a device for the detection of breast cancer, comprising nucleic acid(s) capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting breast cancer, comprising measuring the miRNA in vitro.

The present inventors provide miRNAs useful in the diagnosis and prediction, with high accuracy, of the risk of a subject to suffering from a thrombosis condition. The present invention also provides a method for deciding or recommending initiating a medical anti-thrombotic therapy.

Provided are a novel biomarker for a brain tumor and a method for using the same. A method for detecting a brain tumor, the method comprising the step of detecting specific miRNA as biomarker.

The invention provides methods and compositions for use in diagnosing and treating thyroid cancer.

Embodiments of the present disclosure provide a reagent kit and a method for detecting renal cell carcinoma. The reagent kit includes a set of primer-probe mixes for detecting miRNAs in exosomes. The set of primer-probe mixes includes a reverse transcription primer R-23b for a specific reverse transcription miR-23b-5p target, a universal forward primer Ge—F, a specific reverse primer 23b-R, and a specific probe 23b-P; a reverse transcription primer R-34c for a specific reverse transcription miR-34c-5p target, a universal forward primer Ge—F, a specific reverse primer 34c-R, and a specific probe 34c-P; a reverse transcription primer R-210 for a specific reverse transcription miR-210-3p target, a universal forward primers Ge—F f, a specific reverse primer 210-R, and a specific probe 210-P; and a reverse transcription primer R-508 for a specific reverse transcription miR-508-3p target, a universal forward primer Ge—F, a specific reverse primer 508-R, and a specific probe 508-P.

Compositions containing micropeptides capable of modulating the accumulation of miRs involved in certain pathologies, and the use of these micropeptides for treating the certain pathologies. Also, methods of identifying these micropeptides modulating the accumulation of miRs involved in pathologies. Further, nuclei acids encoding those micropeptides that modulate the accumulation of miRs involved in pathologies.

Disclosed are a tumor biomarker and application thereof, and a tumor detection kit. Patients suffering from non-small cell lung cancer, containing an EML4-ALK or SLC34A2-ROS1 fusion gene, have a specific circular RNA in blood. The base sequences of the circular RNA are represented by SEQ ID NOS. 1-6. The circular RNA is associated with non-small cell lung cancer, stably and constantly exists in plasma samples, and has high specificity and effectiveness, and thus can be used as a biomarker for tumor detection. Reagents such as primers and probes for detecting the circular RNA can be used for preparing the tumor detection kit.